AVITA Medical, Inc. (RCEL)

Market Cap	228.64M
Revenue (ttm)	60.04M
Net Income (ttm)	-57.32M
Shares Out	26.43M
EPS (ttm)	-2.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	176,252
Open	8.70
Previous Close	8.54
Day's Range	8.55 - 8.78
52-Week Range	7.51 - 18.93
Beta	1.58
Analysts	Buy
Price Target	18.00 (+108.09%)
Earnings Date	Feb 13, 2025

About RCEL

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2020
• Employees: 207
• Stock Exchange: NASDAQ
• Ticker Symbol: RCEL
• Website: https://www.avitamedical.com

Financial Performance

In 2023, AVITA Medical's revenue was $50.14 million, an increase of 45.68% compared to the previous year's $34.42 million. Losses were -$35.38 million, 32.7% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for RCEL stock is "Buy." The 12-month stock price forecast is $18.0, which is an increase of 108.09% from the latest price.

Price Target

$18.0

(108.09% upside)

Analyst Consensus: Buy